Clinical trial
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer…
NCT00273338 · Novacea, Industry · Terminated
Key facts
| NCT number | NCT00273338 |
|---|---|
| Title | DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) |
| Official title | A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2) |
| Lead sponsor | Novacea, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | calcitriol, docetaxel |
| Enrollment | 1,200 |
| Start date | Jan 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Jan 9, 2006 |
| Last update posted | Nov 6, 2007 |
| Countries | Canada, Czechia, Germany, Hungary, Puerto Rico, Romania, Serbia and Montenegro, Slovakia, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: